Eledon Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ELDN Nasdaq 2836 eledon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eledon Pharmaceuticals, Inc.

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - Sep 22nd, 2026 5:00 am
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - Sep 9th, 2026 5:00 am
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - Sep 3rd, 2026 5:00 am
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Aug 13th, 2026 2:05 pm
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up - Jul 21st, 2026 7:00 am
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - Jul 8th, 2026 7:15 am
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - Jul 1st, 2026 7:30 am
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Jun 25th, 2026 5:00 am
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus - Jun 22nd, 2026 5:00 am
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? - Jun 16th, 2026 7:40 am
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Jun 10th, 2026 12:22 pm
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - Jun 8th, 2026 5:00 am
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - Jun 4th, 2026 2:31 pm
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes - May 27th, 2026 5:55 am
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress - May 20th, 2026 2:05 pm
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 13th, 2026 2:05 pm
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - May 1st, 2026 2:00 pm
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - Apr 30th, 2026 6:15 am
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money - Apr 20th, 2026 8:14 am